DETERMINE Trial: Capmatinib Treatment in Adult Patients With Cancers Harboring MET Gene Dysregulations

What this Trial Is About

Researchers are evaluating capmatinib, a drug approved for certain lung cancers with a specific METex14 skipping mutation, to see if it is useful in treating other rare or common adult cancers that have mutations or changes in the MET gene. This trial is part of the DETERMINE program, which aims to match existing targeted therapies to rare cancers or cancers with specific genetic alterations, potentially expanding treatment options through the NHS and Cancer Drugs Fund. In this trial, adult patients with cancers harboring MET dysregulations will receive capmatinib orally at a dose of 800 mg daily (400 mg twice a day). Treatment cycles last 28 days, and patients will continue treatment until their disease progresses without benefit, they experience unacceptable side effects, or they choose to stop. Patients will have blood samples collected at various times during treatment and at the end of treatment. After treatment ends, they will be followed up every three months for two years. Participants will undergo screening that includes molecular testing of their tumor and biopsies or blood sample collections. Researchers will perform disease assessments regularly during treatment, typically every two cycles (each 28 days), and less frequently after 24 weeks. Outcomes measured include tumor response, clinical benefit, survival times, and quality of life surveys. Safety monitoring will continue for up to five years after treatment, and follow-up visits will assess participants every three months for two years to observe long-term effects.

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations